The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans

Launched by HENRY FORD HEALTH SYSTEM · Jan 16, 2020

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tranexamic acid to see if it can help reduce skin discoloration caused by conditions known as lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). These conditions can cause dark patches on the skin, and currently, there are no effective treatments available. Tranexamic acid has been effective in treating another skin condition related to pigmentation called melasma, so researchers want to find out if it can work similarly for LPP and EDP.

To participate in this study, you must be 18 years or older and have a diagnosis of LPP, EDP, or a related condition called ashy dermatosis. It's important that you have not used any treatments for your skin discoloration (except sunscreen) for at least a month before joining. Participants will need to fully understand the study rules and risks involved. If you have certain health issues, like a history of blood clotting disorders or are currently pregnant or breastfeeding, you may not be eligible to participate. If you join the trial, you will receive guidance on what to expect throughout the study process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject age 18 and older
• • Subject with a diagnosis of LPP, EDP, or AD
• • Subject able to understand requirements of the study and risks involved
• • Subject able to sign a consent form
• • Subject to have discontinued all topical or oral medications, with the exception of sunscreen, used to treat pigmentary abnormalities one month prior to treatment
• Exclusion Criteria:
• • Personal history of clotting disorder or thromboembolic disease (deep vein thrombosis (DVT), stroke, etc)
• • Active malignancy, excluding non-melanoma skin cancer
• • Moderate to severe renal impairment
• • History of migraine with aura
• • Current anticoagulant therapy
• • Current use of hormonal contraception or hormone replacement therapy in the last 30 days
• • A woman who is lactating, pregnant, or planning to become pregnant